Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending September 2015. The document serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibilities (PDMR), or connected persons, in accordance with DTR 3.1.4R(1)(a).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is limited to specific share transaction disclosures and does not contain consolidated financial statements.
Material Changes
The filing discloses changes in the share interests of Ms. C. Thomas, a Person Discharging Managerial Responsibility. On August 28, 2015, Ms. Thomas acquired Ordinary Shares through the re-investment of dividends from the GSK 2009 Deferred Annual Bonus Plan Post-Tax awards. The transaction details are as follows:
- Share Price: £12.98 per Ordinary Share
- Shares Acquired (Personal Contribution): 174
- Shares Acquired (GSK Matching Contribution): 174
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is strictly a regulatory notification of insider share activity.
Investor Verification Checklist
- Verify the total number of shares held by Ms. C. Thomas post-transaction to assess total exposure.
- Confirm the terms of the GSK 2009 Deferred Annual Bonus Plan Post-Tax awards regarding dividend reinvestment.
- Review the broader context of PDMR trading activity for the quarter to identify any patterns.